Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib Concurrent With Y-90 TARE in Advanced HCC
NCT02288507Phase 1Withdrawn
- Sponsor
- University of Hawaiʻi
- Start
- Nov 2014
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sorafenib in hepatocellular carcinoma (HCC), sponsored by University of Hawaiʻi. Primary endpoint: Adverse events at 2 months. Planned start Nov 2014; status: withdrawn.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02288507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02288507.